top of page

Toward a solution for Shigella/ETEC diarrhoea

SHIGETECVAX is a collaborative project funded by the European Union’s Horizon 2020 research and innovation programme that brings together experts from Austria, Bangladesh, Germany, Sweden and the United States with proven track record in research and development with the aim of advancing a vaccine targeting the major causes of diarrhoeal diseases.  

ShigETECvax Logo.png



Diarrhoeal Disease


01 September 2019 – 28 February 2025


European Vaccine Initiative



European Union Horizon 2020


8.6M Euro

Diarrhoea is the most common disease globally. Although typically being a self-limiting condition in western civilisations, it can be a killer in low- and middle-income countries, where it is a leading cause of death and high morbidity for children under five years of age. 


Under the coordination of the European Vaccine Initiative (EVI), and partners including Eveliqure Biotechnologies (Austria), icddr, b (Bangladesh), University of Gothenburg (Sweden), and PATH (United States), the SHIGETECVAX consortium is dedicated to advancing a radically new approach developed by Eveliqure Biotechnologies. This combination vaccine is designed to prevent infections with Shigella and enterotoxigenic Escherichia coli (ETEC), two bacteria that cause significant cases of diarrhoea and suffering globally. 

No effective vaccines against these two pathogens exist, and this novel vaccine has the potential to provide cost-effective immunization option for populations in and travellers to endemic countries.    

Diarrheal disease fact sheet (7).png
EU emblem_flag_yellow_high (1).jpg

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568

bottom of page